Preadmission Antiplatelet Use and Associated Outcomes and Costs Among ICU Patients With Intracranial Hemorrhage.
Shannon M FernandoGarrick MokBram RochwergShane W EnglishKednapa ThavornVictoria A McCredieDar DowlatshahiJeffrey J PerryEelco F M WijdicksPeter M ReardonPeter TanuseputroKwadwo KyeremantengPublished in: Journal of intensive care medicine (2019)
Among ICU patients admitted with intracranial hemorrhage, preadmission oral antiplatelet use was not associated with increased in-hospital mortality or hospital costs. These findings have important prognostic implications for clinicians who care for patients with intracranial hemorrhage.